Ever Supreme Bio Technology Co., Ltd

Ever Supreme Bio Technology Co., Ltd is a biotechnology company based in Taichung, Taiwan, specializing in the research, development, and manufacture of advanced cell-based therapies. Primarily focused on immune cell and stem cell technologies, the company develops innovative therapeutic candidates addressing critical needs in oncology, cardiovascular diseases, and autoimmune disorders. Its robust pipeline features assets like CAR001—the world’s first allogeneic, mRNA-engineered BiTE-secreting CAR-γδT therapy for solid tumors—as well as products such as umbilical cord mesenchymal stem cells for myocardial infarction and stroke, and dendritic cell vaccines targeting malignant brain tumors. In addition to its clinical development efforts, Ever Supreme Bio Technology is recognized as Taiwan’s largest cell therapy contract development and manufacturing organization (CDMO), serving 19 hospitals and holding a significant market share in domestic biomanufacturing. The company leverages proprietary platforms including immune cell, stem cell, nanocapsule, and exosome technologies, positioning itself at the forefront of next-generation cellular therapy innovation. Through its integrated model—combining product development with high-margin CDMO services—Ever Supreme Bio Technology plays a pivotal role in advancing regenerative medicine and precision therapy within the regional and global biotechnology landscape.